Harvard Medical School, Affiliated Program of Health Sciences and Technology at Massachusetts Institute of Technology, Massachusetts General Hospital
Dr. David J. Kuter is a professor of medicine at both Harvard Medical School and the Affiliated Program of Health Sciences and Technology at Massachusetts Institute of Technology and the director of Clinical Hematology at Massachusetts General Hospital in Boston.
Dr. Kuter is a former Rhodes Scholar who earned a research doctorate in philosophy at Magdalen College of Oxford University and a medical degree at Harvard Medical School. He completed an internship and residency in internal medicine at Massachusetts General Hospital in Boston, clinical and research fellowships in medicine at Harvard Medical School, and a fellowship in hematology-oncology at Massachusetts General Hospital. He also completed a visiting scientist and postdoctoral fellowship in the Department of Biology at the Massachusetts Institute of Technology in Cambridge.
Board certified in internal medicine, hematology, and medical oncology, Dr. Kuter chairs the Heparin-Induced Thrombocytopenia Subcommittee of the National Institutes of Health Network for Transfusion Medicine and Hemostasis. He is also a member of the International Society for Experimental Hematology and American Society of Hematology.
Dr. Kuter is active in the training of hematology/oncology fellows, developing curricula, organizing and giving lectures, and supervising rounds. He is director of the Hematology Course for the Health Sciences and Technology division of Harvard Medical School. He has received three prestigious teaching awards from Massachusetts General Hospital and Harvard Medical School. He has authored numerous articles, reviews, chapters, books, editorials, and clinical communications. Dr. Kuter has dedicated years of effort to researching coagulopathies, anticoagulation, and platelet disorders. As one of the original discoverers of thrombopoietin, in recent years, Dr. Kuter has conducted groundbreaking clinical research into the development of effective thrombopoietic agents.
You need to be logged in to save this episode to a playlist.